Abbott evolves to focus on diagnostics, with new high-sensitivity heart attack diagnostic test

摘要

Healthcare giant Abbott, and a senior medical devices analyst from GlobalData asserts that the company's latest cardiac diagnostics product represents the first step in a line of new diagnostic products which will act to deliver growth over the next few years. Abbott announced in 2011 that it planned to separate into two companies, one in medical products including devices and diagnostics, and the other in research-based pharmaceuticals, and this separation was made official on January 1 this year. With the medical products company keeping the Abbott name, the research- based pharmaceutical company is now named AbbVie, and will feature billion dollar blockbuster drug Humira among its products.